Buscar en
Allergologia et Immunopathologia
Toda la web
Inicio Allergologia et Immunopathologia Is palivizumab effective as a prophylaxis of respiratory syncytial virus infecti...
Journal Information
Vol. 43. Issue 3.
Pages 298-303 (May - June 2015)
Share
Share
Download PDF
More article options
ePub
Vol. 43. Issue 3.
Pages 298-303 (May - June 2015)
Point of view
DOI: 10.1016/j.aller.2013.09.003
Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis
Visits
...
M. Sánchez-Solisa,
Corresponding author
msolis@um.es

Corresponding author.
, S. Gartnerb, V. Bosch-Gimenezc, L. Garcia-Marcosa
a Pediatric Pulmonology Unit, “Virgen de la Arrixaca” Children's University Hospital, University of Murcia, Murcia, Spain
b Pediatric Pulmonology and Cystic Fibrosis Units, “Vall d’Hebron” Children's University Hospital, Autonomous University of Barcelona, Barcelona, Spain
c Neonatology Unit, “Virgen de la Arrixaca” Children's University Hospital, University of Murcia, Murcia, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (2)
Table 1. Characteristics of the selected studies.
Table 2. Patients included in the meta-analysis.
Show moreShow less
Abstract
Background

Infections by respiratory syncytial virus (RSV) are more severe in patients with cystic fibrosis (CF), and many CF units use palivizumab as prophylaxis; however, information about palivizumab efficacy in CF patients is almost lacking.

Methods

A literature search up to December 2012 on the morbidity of RSV bronchiolitis in CF patients and on the safety and efficacy of palivizumab in those patients was performed. A random-effects meta-analysis was conducted for those studies meeting pre-specified search criteria. Historical controls were allowed.

Results

The number of patients who received palivizumab was 354 and the hospital admission rate was 0.018 (95% CI 0.0077–0.048). The corresponding number in the non-treated groups was 463 patients with an admission rate of 0.126 (95% CI 0.086–0.182) (Q=13.9; p<0.001).

Conclusion

Palivizumab may have a role in the prevention of severe lower airway infection by RSV in CF patients.

Keywords:
Respiratory syncytial virus
Bronchiolitis
Cystic fibrosis
Admission rate
Prophylaxis
Palivizumab

Article

These are the options to access the full texts of the publication Allergologia et Immunopathologia
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Allergologia et Immunopathologia

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 22,50 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.